Keeping you up to date on recent developments in orthopedics, including: IMPACT study shows 25% reduction in health care costs associated with earlier prosthetic care; Human growth hormone treatment after ACL injury may prevent loss of muscle strength; Osteoporosis treatment may also protect against pneumonia.
Lowell, Mass.-based startup Launchpad Medical LLC has picked up an additional $1.8 million grant from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center to advance the development of its bone graft solution. The company plans to use the funds to conduct a pivotal animal study of the injectable biomaterial, which will pave the way for a U.S. FDA-approved clinical trial.
Keeping you up to date on recent developments in orthopedics, including: Cell 'pores' discovery gives hope to millions of brain and spinal cord injury patients; Little skates could hold the key to cartilage therapy in humans; Spinal cord injury increases risk for mental health disorders.
PERTH, Australia – Perth-based regenerative medicine company Orthocell Ltd. has submitted a 510(k) application to the U.S. FDA for its Celgro collagen medical device for dental guided bone and soft tissue regeneration applications. The submission follows positive results from an FDA-guided bone regeneration study, which is a key component toward the goal of gaining U.S. marketing approval.
Keeping you up to date on recent developments in orthopedics, including: Lab engineers 3D-functional bone tissues; Comparison of early postoperative pain after first vs. second total knee arthroplasty; Vitamin B3 revitalizes energy metabolism in muscle disease; Worldwide IOF-ISCD survey of bone densitometry units published.
Keeping you up to date on recent developments in orthopedics, including: UCLA scientists create first roadmap of human skeletal muscle development; Excess coffee consumption a culprit for poor health; Arthritis clinical trial shows support for dextrose injection to alleviate knee pain; Gene therapy in mice builds muscle, reduces fat.
Keeping you up to date on recent developments in orthopedics, including: Scientists regenerate neurons in mice with spinal cord injury and optic nerve damage; Trial questions benefits of organic nitrates for bone health; Mind-controlled arm prostheses that 'feel' are now a part of everyday life; Biomaterial immune control discoveries could reduce implant rejection.
Despite a drop off in elective procedures due to the COVID-19 pandemic, Stryker Corp., of Kalamazoo, Mich., unveiled first-quarter results that came in better than analysts had presumed. BTIG’s Ryan Zimmerman noted that, unlike other companies, Stryker did not pre-announce preliminary revenue. And while investors were concerned that the company would be adversely affected by the slump in elective procedures, "the diversity of the portfolio helped to offset procedure declines in late March.”
Carmell Therapeutics Corp., of Pittsburgh, received fast track designation from the U.S. FDA for its first product, CT-101, a bone healing accelerant. Carmell is gearing up for a phase III study of the plasma-based bioactive accelerant as part of its pursuit of a biologic license application.
Keeping you up to date on recent developments in orthopedics, including: Physio support in COVID-19 recovery; Co-delivery of IL-10 and NT-3 to enhance spinal cord injury repair; European countries face a costly 23% increase in fragility fractures by 2030.
RSS
